Compare Novartis AG (NVS) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Star Bulk Carriers Corp — how do they compare? Novartis AG trades at $142.74 (market cap $274.00B), while Star Bulk Carriers Corp trades at $30.36 (market cap $3.45B). The key difference: Novartis AG is far larger — about 79.4× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.33%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Star Bulk Carriers Corp for 24 Days on average.
| NVS | SBLK | |
|---|---|---|
Market Cap | $274.00B | $3.45B |
Volume | 1,852,137 | 1,355,871 |
Sector | Health | Industrials |
52-Week High | $168.62 | $32.49 |
52-Week Low | $121.80 | $16.79 |
Typical Hold Time | 82 Days | 24 Days |
Enterprise Value | $315.32B | $4.13B |
Dividend Yield | 3.31% | 6.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Star Bulk Carriers (SBLK) trades at $29.69, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. Fundamentally, the company shows strong profitability with a 23.87% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights insider buying and a declared $0.90 dividend for H2 2026, reflecting management confidence.
The outlook is positive given robust earnings performance and attractive valuation multiples, though near-term technical weakness and reliance on shipping market cycles pose risks. Analyst consensus is bullish with 14 buy ratings, supporting potential upside if operational strength continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
